Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Allergan
Age
18–50
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
At least a 1-year history of migraine with or without aura consistent with a diagnosis according to the International Classification of Headache Disorders, 3rd edition, (ICHD-3, 2018)
By history, the participant's migraines typically last between 4 and 72 hours if untreated or treated unsuccessfully and migraine episodes are separated by at least 48 hours of headache pain freedom
History of at least 2 migraine attacks per month in the 2 months prior to Screening
Have a sitting pulse rate ≥ 45 beats per minute (bpm) and ≤ 100 bpm during the vital sign assessment at the Screening Visit. Clinical site may perform a maximum of 2 repeats of vital sign measurements if the initial measurement is out of range.
Negative test results for benzoylecgonine (cocaine), methadone, barbiturates, amphetamines, benzodiazepines, cannabinoids, opiates, and phencyclidine at the Screening Visit and Day -1; unless explained by concomitant medication use (eg, opioids prescribed for migraine pain)
Participants willing to minimize the risk of inducing pregnancy for the duration of the clinical study and follow-up period
You may not be if
Difficulty distinguishing migraine headache from tension-type or other headaches
Has a history of migraine aura with diplopia or impairment of level of consciousness, hemiplegic migraine, or retinal migraine as defined by ICHD-3
Has a current diagnosis of new persistent daily headache, trigeminal autonomic cephalgia (eg, cluster headache), or painful cranial neuropathy as defined by ICHD-3
Required hospital treatment of a migraine attack 3 or more times in the 6 months prior to Screening
Has a chronic non-headache pain condition requiring daily pain medication (with the exception of pregabalin)
Has clinically significant cardiovascular or cerebrovascular disease per the investigator's opinion
Previously participated in an investigational study of ubrogepant
Participation in any other clinical investigation using an experimental drug within 30 days prior to study intervention administration
Participation in a blood or plasma donation program within 60 or 30 days, respectively, prior to study intervention administration
